Context Therapeutics Valuation
| CNTX Stock | USD 1.36 0.03 2.16% |
Today, the firm appears to be undervalued. Context Therapeutics shows a prevailing Real Value of $1.92 per share. The current price of the firm is $1.36. Our model approximates the value of Context Therapeutics from analyzing the firm fundamentals such as Shares Owned By Insiders of 1.44 %, current valuation of 19.69 M, and Return On Equity of -0.3 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Context Therapeutics' valuation include:
Price Book 1.2432 | Enterprise Value 19.7 M | Enterprise Value Ebitda 1.5966 |
Undervalued
Today
Please note that Context Therapeutics' price fluctuation is dangerous at this time. Calculation of the real value of Context Therapeutics is based on 3 months time horizon. Increasing Context Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Context Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Context Stock. However, Context Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.36 | Real 1.92 | Target 3.7 | Hype 1.22 |
The intrinsic value of Context Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Context Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Context Therapeutics helps investors to forecast how Context stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Context Therapeutics more accurately as focusing exclusively on Context Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Context Therapeutics' intrinsic value based on its ongoing forecasts of Context Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Context Therapeutics' closest peers.
Context Therapeutics Cash |
|
Context Valuation Trend
Analysing the historical paterns of Context Therapeutics' enterprise value and its market capitalization is a good way to estimate and gauge the value of Context Therapeutics over time and is usually enough for investors to make rational market timing decisions.
Context Therapeutics Total Value Analysis
Context Therapeutics is currently anticipated to have valuation of 19.69 M with market capitalization of 104.25 M, debt of 4.19 M, and cash on hands of 42.92 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Context Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
19.69 M | 104.25 M | 4.19 M | 42.92 M |
Context Therapeutics Asset Utilization
One of the ways to look at asset utilization of Context is to check how much profit was generated for every dollar of assets it reports. Context Therapeutics shows a negative utilization of assets of -0.19 percent, losing $0.001919 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Context Therapeutics shows how discouraging it operates for each dollar spent on its assets.Context Therapeutics Ownership Allocation
Context Therapeutics holds a total of 75 Million outstanding shares. The majority of Context Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Context Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Context Therapeutics. Please pay attention to any change in the institutional holdings of Context Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Context Therapeutics Profitability Analysis
Net Loss for the year was (23.96 M) with profit before overhead, payroll, taxes, and interest of 0.About Context Therapeutics Valuation
Our relative valuation model uses a comparative analysis of Context Therapeutics. We calculate exposure to Context Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Context Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -12 K | -11.4 K |
Context Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 16 M |
Context Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Context Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Context we look at many different elements of the entity such as Context's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Context Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Context Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Context Therapeutics' worth.Additional Tools for Context Stock Analysis
When running Context Therapeutics' price analysis, check to measure Context Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Context Therapeutics is operating at the current time. Most of Context Therapeutics' value examination focuses on studying past and present price action to predict the probability of Context Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Context Therapeutics' price. Additionally, you may evaluate how the addition of Context Therapeutics to your portfolios can decrease your overall portfolio volatility.